RESCRIPTOR
LOE ApproachingNDAORALTABLETPriority Review
Approved
Apr 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RESCRIPTOR is an oral small-molecule tablet approved in 1997 by GSK. The exact indication and mechanism of action are not specified in available data, but the product is positioned as an NDA drug in the antiretroviral or antiviral space based on historical context. It represents a mature therapeutic asset approaching loss of exclusivity.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely in transition mode with reduced headcount and focus on managed decline or niche positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
Started Dec 2003
3 enrolled
HIV-1 Infection
Career Relevance
Zero linked job openings indicate minimal active hiring for RESCRIPTOR. Working on this product offers limited career advancement and stability concerns, as the brand is in managed decline with reduced organizational investment and headcount.
Brand Manager
Worked on RESCRIPTOR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.